Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty
Osteoarthritis, Knee
About this trial
This is an interventional treatment trial for Osteoarthritis, Knee focused on measuring Tranexamic acid, Peri-articular injection, Total knee arthroplasty, Blood loss, Osteoarthritis, Knee
Eligibility Criteria
Inclusion Criteria:
- adult patients with osteoarthritis in need of a TKA
Exclusion Criteria:
- inflammatory arthritis
- post-traumatic arthritis
- a history of or current venous thromboembolic disease
- any underlying disease of haemostasis
- cirrhosis
- chronic renal failure
- patients on anticoagulants or strong antiplatelet drugs (e.g. warfarin, clopidogrel)
- know allergy to TXA
- defective color vision
- preoperative hemoglobin <10 g/dL
- platelet count < 140,000 /uL3
Sites / Locations
- Orthopaedic department, Thammasat university hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Peri-articular group
Intravenous group
Patients received 750 mg of peri-articular Tranexamic acid (Transamin®; OLIC Thailand Ltd, Bangkok, Thailand; 250 mg/5 mL, 15 cc total volume) injection into the soft tissue around medial capsule (5 ml), lateral capsule (5 ml) and around the quadriceps muscle (5 ml), 10 minutes prior to deflating the tourniquet and wound closure.
Patients received 750 mg of intravenous tranexamic acid(250 mg/5 ml, 15 cc total volume, keeping within the therapeutic range of 10-15 mg/kg/dose), 10 minutes prior to deflating the tourniquet and wound closure.